BioAge Labs to Detail Pipeline Progress at Oppenheimer Conference
Event summary
- BioAge Labs CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat at the Oppenheimer Healthcare Life Sciences Conference on February 26, 2026.
- The conference takes place February 25-26, 2026.
- One-on-one meetings between Fortney and Goldstein are also scheduled.
- Webcast replays will be available on the company's investor relations website for 30 days.
The big picture
BioAge Labs is pursuing a novel therapeutic approach targeting the biology of aging to treat metabolic diseases, a strategy gaining traction as the aging population expands and healthcare costs rise. The company's reliance on a proprietary discovery platform and lead candidate, BGE-102, creates both opportunity and risk. The Oppenheimer conference provides a key venue for BioAge to communicate progress and manage investor expectations amidst increasing competition in the longevity therapeutics space.
What we're watching
- Clinical Progress
- The presentation will likely focus on topline data from the Phase 1 SAD/MAD trial of BGE-102, anticipated in 1H26, and the market will scrutinize the safety and tolerability profile revealed.
- Pipeline Breadth
- Given the company’s focus on aging biology, the extent to which BioAge highlights its preclinical programs beyond BGE-102 and APJ agonists will indicate the depth of its discovery platform and long-term potential.
- Financial Health
- With Dov Goldstein, CFO, participating, investors will be looking for any signals regarding the company’s cash runway and financing plans to support its expanding clinical programs.
Related topics